Literature DB >> 25232477

Prevention of Perinatal Hepatitis B Virus Transmission.

Noele P Nelson1, Denise J Jamieson2, Trudy V Murphy1.   

Abstract

Hepatitis B virus (HBV) infection, the most common form of chronic hepatitis worldwide, is a major public health problem affecting an estimated 360 million people globally. Mother-to-child transmission (MTCT) is responsible for more than one third of chronic HBV infections worldwide. An estimated 15%-40% of persons chronically infected develop HBV-related complications, such as cirrhosis and hepatic carcinoma, and 25% die from these complications. MTCT can occur during pregnancy or during delivery. Screening pregnant women for HBV infection, providing infant postexposure prophylaxis, and maternal treatment with antiviral medications are strategies for reducing MTCT transmission rates and the global burden of new chronic HBV infections. Administration of hepatitis B immune globulin (HBIG) and hepatitis B (HepB) vaccine within 24 hours of birth, followed by completion of the vaccine series, is 85%-95% efficacious for prevention of MTCT. Despite timely post-exposure prophylaxis, MTCT occurs in 5%-15% of infants. Hepatitis B surface antigen (HBsAg) positive, hepatitis e antigen (HBeAg) positive mothers with HBV DNA level ≥10(6) copies/mL (>200 000 IU/mL) are at greatest risk of transmitting HBV to their infants. Consensus recommendations and evidence-based guidelines for management of chronic HBV infection and screening of pregnant women have been developed. The safety and efficacy of antiviral drug use during pregnancy are areas of ongoing research. Substantial advances have been achieved globally in reducing MTCT, but MTCT remains an ongoing health problem. Attaining a better understanding of the mechanisms of MTCT, implementing existing policies on maternal screening and infant follow-up, and addressing research gaps are critical for further reductions in MTCT transmission. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  antivirals; hepatitis B; hepatitis B immune globulin; hepatitis B vaccine; hepatitis B virus; mother-to-child transmission; perinatal transmission

Year:  2014        PMID: 25232477      PMCID: PMC4164184          DOI: 10.1093/jpids/piu064

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  37 in total

Review 1.  An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus.

Authors:  Calvin Q Pan; Zhong-Ping Duan; Kalyan R Bhamidimarri; Huai-Bin Zou; Xiao-Feng Liang; Jie Li; Myron J Tong
Journal:  Clin Gastroenterol Hepatol       Date:  2011-11-09       Impact factor: 11.382

Review 2.  Chronic hepatitis B infection and pregnancy.

Authors:  Michelle L Giles; Kumar Visvanathan; Sharon R Lewin; Joe Sasadeusz
Journal:  Obstet Gynecol Surv       Date:  2012-01       Impact factor: 2.347

Review 3.  Treatment of chronic hepatitis B in children.

Authors:  Maureen M Jonas
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-07       Impact factor: 2.839

4.  The presence and expression of the hepatitis B virus in human oocytes and embryos.

Authors:  X L Hu; X P Zhou; Y L Qian; G Y Wu; Y H Ye; Y M Zhu
Journal:  Hum Reprod       Date:  2011-04-12       Impact factor: 6.918

5.  Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention.

Authors:  Wan-Hsin Wen; Mei-Hwei Chang; Lu-Lu Zhao; Yen-Hsuan Ni; Hong-Yuan Hsu; Jia-Feng Wu; Pei-Jer Chen; Ding-Shinn Chen; Huey-Ling Chen
Journal:  J Hepatol       Date:  2013-02-26       Impact factor: 25.083

6.  The influence of age on the development of the hepatitis B carrier state.

Authors:  W J Edmunds; G F Medley; D J Nokes; A J Hall; H C Whittle
Journal:  Proc Biol Sci       Date:  1993-08-23       Impact factor: 5.349

7.  Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity.

Authors:  R del Canho; P M Grosheide; J A Mazel; R A Heijtink; W C Hop; L J Gerards; G C de Gast; W P Fetter; J Zwijneberg; S W Schalm
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

8.  Presence of HBV DNA in spermatozoa: a possible vertical transmission of HBV via the germ line.

Authors:  M Hadchouel; J Scotto; J L Huret; C Molinie; E Villa; F Degos; C Brechot
Journal:  J Med Virol       Date:  1985-05       Impact factor: 2.327

9.  Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism.

Authors:  Han Bai; Lin Zhang; Li Ma; Xiao-Guang Dou; Guo-He Feng; Gui-Zhen Zhao
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 10.  Hepatitis and reproduction.

Authors: 
Journal:  Fertil Steril       Date:  2008-11       Impact factor: 7.329

View more
  15 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  Estimating Annual Births to Hepatitis B Surface Antigen-Positive Women in the United States by Using Data on Maternal Country of Birth.

Authors:  Alaya Koneru; Sarah Schillie; Henry Roberts; Barry Sirotkin; Nancy Fenlon; Trudy V Murphy; Noele P Nelson
Journal:  Public Health Rep       Date:  2019-04-03       Impact factor: 2.792

Review 3.  Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities.

Authors:  Jodie Dionne-Odom; Basile Njei; Alan T N Tita
Journal:  Clin Ther       Date:  2018-07-05       Impact factor: 3.393

4.  Assessment of State Perinatal Hepatitis B Prevention Laws.

Authors:  Lindsay A Culp; Lisa Caucci; Nancy E Fenlon; Megan C Lindley; Noele P Nelson; Trudy V Murphy
Journal:  Am J Prev Med       Date:  2016-12       Impact factor: 5.043

5.  Impact of HAART Therapy and HIV Infection over Fetal Growth-An Anthropometric Point of View.

Authors:  Daniela Roxana Matasariu; Mircea Onofriescu; Elena Mihalceanu; Carmina Mihaiela Schaas; Iuliana Elena Bujor; Alexandra Maria Tibeica; Alexandra Elena Cristofor; Alexandra Ursache
Journal:  Microorganisms       Date:  2022-05-30

Review 6.  Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.

Authors:  Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson
Journal:  Int J Toxicol       Date:  2020 Mar/Apr       Impact factor: 2.032

7.  Prevalence of hepatitis B virus among children of HBsAg-positive mothers in Hebron district, Palestine.

Authors:  Shefa Al-Amleh
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

8.  Prevalence, infectivity and correlates of hepatitis B virus infection among pregnant women in a rural district of the Far North Region of Cameroon.

Authors:  Jean Jacques N Noubiap; Jobert Richie N Nansseu; Shalom Tchokfe Ndoula; Jean Joel R Bigna; Ahmadou M Jingi; Joël Fokom-Domgue
Journal:  BMC Public Health       Date:  2015-05-02       Impact factor: 3.295

9.  Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencing.

Authors:  Yushen Du; Xiumei Chi; Chong Wang; Jing Jiang; Fei Kong; Hongqing Yan; Xiaomei Wang; Jie Li; Nicholas C Wu; Lei Dai; Tian-Hao Zhang; Sara Shu; Jian Zhou; Janice M Yoshizawa; Xinmin Li; Debika Bhattacharya; Ting-Ting Wu; Junqi Niu; Ren Sun
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies.

Authors:  Moussa Lingani; Tomoyuki Akita; Serge Ouoba; Armel Moumini Sanou; Aya Sugiyama; Zekiba Tarnagda; Masayuki Ohisa; Halidou Tinto; Shunji Mishiro; Junko Tanaka
Journal:  BMC Public Health       Date:  2018-04-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.